Soon-Shiong’s NantHealth tanks on STAT report of self-dealing; Bioversys, Aptuit forge antibiotic collab; Helix gets new CEO

STAT reported that biotech billionaire Patrick Soon-Shiong used a $12 million “gift” to the University of Utah as a carefully disguised boost to his cancer business, steering $10 million of that back into his hands under a contract that has raised questions about the way the money was handled. And the report has taken a big bite out of the share price of NantHealth $NH, which dropped 23%.

→ Basel-based Bioversys AG and Aptuit launched a joint collaboration aimed at the discovery of novel targets and molecules for Gram-negative bacteria.

→ Toronto-based Helix BioPharma has recruited a new CEO. CSO Heman Chao is adding the CEO title to his job description while Sven Rohmann will be chairman of the board as well as a strategic adviser.

→ San Francisco-based Velano Vascular has raised $17 million as it starts commercialization work on new, needle-free tech for drawing blood in hospitals.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy

EvaluatePharma World Preview 2017